Wordt geladen...
Sorafenib exerts anti-glioma activity in vitro and in vivo
Despite conventional treatment strategies glioblastoma, the most common malignant primary brain has a bad prognosis with median survival times of 12-15 month. In this study, the efficacy of sorafenib (Nexavar, BAY43-9006), a multikinase inhibitor, on glioblastoma cells was evaluated both in vitro an...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3198851/ https://ncbi.nlm.nih.gov/pubmed/20470863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neulet.2010.05.009 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|